Physician profile
Heather Klavan
NPI 1619243599
$8,650.54
in general payments reported to CMS, 2019-2025
37 companies · $953 in 2025
The $953 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,021 · 2020: $1,790 · 2021: $1,388 · 2023: $21.37 · 2024: $1,477 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Long Term Medical Supply Or Device Loan: $194 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.14 |
| Long Term Medical Supply Or Device Loan | $193.55 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,487.51 | 2019-2024 | Trulance |
| Abbvie INC. | $1,211.56 | 2019-2025 | |
| Apollo Endosurgery US INC | $1,084.12 | 2019 | |
| Qol Medical, LLC | $837.98 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $535.78 | 2019-2025 | Entyvio |
| Pfizer INC. | $425.48 | 2019-2025 | |
| Janssen Biotech, INC. | $340.97 | 2019-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $269.65 | 2019-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $261.19 | 2019-2021 | |
| Genzyme Corporation | $207.83 | 2024-2025 | |
| Corcept Therapeutics | $199.10 | 2024-2025 | Korlym |
| Pentax of America, INC. | $193.55 | 2024 | Video Colonoscope |
| Madrigal Pharmaceuticals | $182.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $139.10 | 2019 | |
| Intercept Pharmaceuticals, INC. | $122.83 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $117.52 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $116.74 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $113.96 | 2024 | |
| Ironwood Pharmaceuticals, INC | $85.22 | 2019-2021 | |
| Redhill Biopharma INC. | $78.38 | 2020-2021 | |
| Braintree Laboratories, INC. | $77.33 | 2019-2024 | Suflave, Sutab |
| Ucb, INC. | $73.96 | 2025 | Bimzelx |
| Phathom Pharmaceuticals, INC. | $70.71 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $63.69 | 2019-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $56.44 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $46.47 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $43.63 | 2024 | Lupkynis |
| Amgen INC. | $35.97 | 2025 | Evenity |
| Endo Pharmaceuticals INC. | $32.71 | 2020-2021 | |
| Ibsa Pharma INC. | $23.59 | 2025 | Tirosint, Flector, Licart |
| Romark Laboratories, Lc | $20.75 | 2020 | |
| Blueprint Medicines Corporation | $19.51 | 2024 | Ayvakit |
| Mallinckrodt Hospital Products INC. | $19.23 | 2025 | Acthar |
| Novo Nordisk INC | $19.00 | 2025 | Wegovy |
| Celltrion USA INC. | $16.89 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $14.63 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $5.40 | 2023 | Lesion Hunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Klavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.